



May 1, 2014

Intra-Cellular Therapies to Present at the Deutsche Bank 39th Annual Health Care Conference

NEW YORK, May 1, 2014 /GLOBE NEWSWIRE/ -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, will present at the Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8, 2014, at 1:30 P.M. Eastern Time in Boston, MA. Dr. Mates will provide a corporate overview and business update.

The live and archived webcast of the company presentation can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at <http://www.intracellulartherapies.com>. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software. The archived replay will be available on the Intra-Cellular Therapies website for one week following the conference.

About Intra-Cellular Therapies

Intra-Cellular Therapies (the "Company") is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the central nervous system ("CNS"). The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders. In December 2013, the Company announced positive topline results from the Company's randomized, placebo- and active-controlled Phase II clinical trial of ITI-007 in patients with acutely exacerbated schizophrenia. This study showed a statistically significant improvement in symptoms associated with schizophrenia at the 60 mg dose on the trial's pre-specified primary endpoint and a favorable safety profile. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of cognitive deficits in schizophrenia and other CNS disorders. The Company has partnered its lead PDE1 compound, ITI-214, and backups from this platform with the Takeda Pharmaceutical Company. ITI-214 has finished the first Phase 1 clinical trial and is now in subsequent Phase 1 trials. The Company is also developing inhibitors against additional targets for CNS indications such as Alzheimer's disease, Parkinson's disease and depression and non-CNS indications such as cardiovascular disease.

Contact:

Juan Sanchez, M.D.
Vice President
Corporate Communications and Investor Relations
Intra-Cellular Therapies, Inc.
212-923-3344

Burns McClellan, Inc.
Lisa Burns/Angeli Kolhatkar (Investors)
Justin Jackson (Media)
jjackson@burnsmc.com
212-213-0006